Breathe Well Live Well
Condition: Inadequately Controlled Asthma
Intervention: Biological: Tralokinumab open-label
Sponsor: AstraZeneca
Not yet recruiting – verified September 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Lung Disease News |
Study Shows Tralokinumab Does Not Significantly Reduce Asthma Exacerbations in …
Lung Disease News Results from a recent study published in The Lancet Respiratory Medicine showed that Tralokinumab did not significantly reduce the rates of asthma exacerbation in patients with severe uncontrolled asthma. However, the results revealed that tralokinumab … |
View full post on asthma – Google News
|
Tralokinumab does not significantly reduce asthma exacerbations
Healio The analysis included 452 adults aged 18 to 75 years with severe uncontrolled asthma. Researchers randomly assigned patients to receive either 300 mg of tralokinumab every 2 weeks for 50 weeks (n = 150), every 2 weeks for 12 weeks and then every 4 … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Biological: Tralokinumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified May 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Oral Corticosteroid Dependent Asthma
Interventions: Biological: Tralokinumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
AstraZeneca starts Phase III program for asthma drug tralokinumab
Pharmaceutical Business Review AstraZeneca has started the Phase III program for an investigational human monoclonal antibody tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by the company's global biologics research and … |
View full post on asthma – Google News
Condition: Uncontrolled Asthma
Interventions: Biological: Tralokinumab; Biological: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified July 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days